<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03511898</url>
  </required_header>
  <id_info>
    <org_study_id>THR-149-001</org_study_id>
    <nct_id>NCT03511898</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)</brief_title>
  <official_title>A Phase 1, Open-label, Multicenter, Dose Escalation Study to Evaluate the Safety of a Single Intravitreal Injection of THR-149 for the Treatment of Diabetic Macular Edema (DME)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ThromboGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ThromboGenics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to evaluate the safety of a single intravitreal injection of THR-149.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2018</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities up to the Day 14 visit</measure>
    <time_frame>up to Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of systemic and ocular adverse events including serious adverse events up to the end of the study</measure>
    <time_frame>From Day 0 up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of laboratory abnormalities up to the end of the study</measure>
    <time_frame>At Screening, Day 1, Day 7, Day 28 and Day 84</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>THR-149 dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>THR-149 dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>THR-149 dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THR-149 dose level 1</intervention_name>
    <description>single intravitreal injection of THR-149 dose level 1</description>
    <arm_group_label>THR-149 dose level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THR-149 dose level 2</intervention_name>
    <description>single intravitreal injection of THR-149 dose level 2</description>
    <arm_group_label>THR-149 dose level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THR-149 dose level 3</intervention_name>
    <description>single intravitreal injection of THR-149 dose level 3</description>
    <arm_group_label>THR-149 dose level 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 18 years or older

          -  Type 1 or type 2 Diabetes Mellitus

          -  Central-involved DME with central subfield thickness of ≥ 320µm on Spectralis®
             spectral domain optical coherence tomography (SD-OCT) or ≥ 305µm on non-Spectralis
             SD-OCT, in the study eye

          -  Best-corrected visual acuity (BCVA) ≤ 57 and ≥ 23 ETDRS letter score in the study eye

          -  Non-proliferative diabetic retinopathy of any stage, or quiescent proliferative
             diabetic retinopathy, in the study eye

          -  Written informed consent obtained from the subject prior to screening procedures

        Exclusion Criteria:

          -  Macular edema due to causes other than DME

          -  Concurrent disease in the study eye, other than central-involved DME, that could
             compromise BCVA, require medical or surgical intervention during the study period or
             could confound interpretation of the results

          -  Any condition that could confound the ability to detect a change in central subfield
             thickness in the study eye

          -  Previous confounding treatments / procedures, or their planned / expected use during
             the study period

          -  Uncontrolled glaucoma in the study eye

          -  Any active ocular / intra-ocular infection or inflammation in either eye

          -  Poorly controlled Diabetes Mellitus

          -  Uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Department</last_name>
    <role>Study Director</role>
    <affiliation>ThromboGenics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Global Clinical Development</last_name>
    <phone>+32 (0)16 751 310</phone>
    <email>info@thrombogenics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>Huntingdon Valley</city>
        <state>Pennsylvania</state>
        <zip>19006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retinal Research Center, PLLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2018</study_first_submitted>
  <study_first_submitted_qc>April 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2018</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

